PPARG and obesity disorder: Furthermore, evidence from studies of VCE-004.8 concludes that it acts on PPARγ (peroxisome proliferator-activated receptor gamma) as a partial agonist but lacks adipogenic activity reducing the metabolic disruption and inflammatory processes that are associated with obesity (del Rio et al. 2016; Palomares et al. 2018).